Navigation Links
Spherics, Inc. Successful Bidder May Make MHRA Submission
Date:8/20/2008

WELLESLEY HILLS, Mass., Aug. 20 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all pharmaceutical intellectual property will be sold at a sealed bid auction on October 10, 2008.

One of the pieces of intellectual property for sale is its lead product, SRx-502, Topiramate Extended Release, a once-a-day version of a branded drug that currently has more than $2 billion in U.S. sales despite twice daily dosing and an unfavorable AE profile. A clear clinical pathway for SRx-502 has been defined by the MHRA for a regulatory submission. A successful bidder may make a new drug submission in 4Q 2009 with the remaining total cost to bring to market expected to cost $7 million.

Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's office -- jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package and access to the Spherics electronic data room.

About Spherics

Spherics has built a strong intellectual property position around its drug delivery technologies and products. The Company has a broad range of issued US and international patents through exclusive licenses from Brown University. These patents cover polyanhydride-based bioadhesive polymers and PIN. In addition to these issued patents, Spherics has filed numerous applications covering compositions of matters of its proprietary polymers (SPHEROMERS), novel oral delivery systems (including BIOGIT, BIOROD and PIN), manufacturing methods, methods of use, formulations and product compositions.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-four (34) years. His most recent Assignment for the Benefit of Creditors in the Biotech field was ActivBiotics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net


'/>"/>
SOURCE Spherics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherics, Inc. Assigns Assets to Joseph F. Finn, Jr., C.P.A.
2. Spherics, Inc. Successful Bidder May Make NDA Submission
3. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
4. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
5. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
6. Life on Mars pregnancy test successfully launched
7. Of mice and men: new male contraceptives successful in rodents and humans
8. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
9. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
10. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
11. James Webb Space Telescope marks successful completion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... ... a unique intellectual property (IP) sharing and commercialization model. , The Center for ... A main component of this effort is bringing the IP to the attention ...
(Date:4/19/2017)... ... 18, 2017 , ... The Vibrating Orifice Aerosol Generator (VOAG) ... monodisperse droplets of known diameters for research applications such as for calibrating droplet ... drying monodisperse droplets. , The VOAG requires forcing liquid out of an ...
(Date:4/19/2017)... ... , ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial ... its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. announced ... of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. ...
(Date:4/19/2017)... PORTLAND, Oregon and PUNE, India , April 19, ... titled, "Membrane Microfiltration Market: Global Opportunity Analysis and Industry Forecast, 2014-2022 ," ... to garner $12,858 million by 2022, registering a CAGR of 9.6% from 2016 ... ... ...
Breaking Biology Technology:
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
(Date:3/16/2017)... Germany , March 16, 2017 CeBIT 2017 - Against identity ... Continue Reading ... Used combined in one project, multi-biometric solutions provide ... Used ... Systems) ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 ... and 23andMe , the leading personal genetics company, ... Zipongo can now provide customers with personalized nutrition plans ... and biometrics, but also genetic markers impacting how their ... Zipongo,s personalized food decision support platform uses biometrics such ...
Breaking Biology News(10 mins):